Abstract
In this study we statistically analyzed the efficacy of concurrent chemoradiotherapy （CCRT） on a total of 54 cases with hypopharyngeal and laryngeal squamous cell cancers that had been primarily treated from 2006 at our hospital.
The results were as follows: with hypopharyngeal cancer/laryngeal cancer the 2-year overall survival rates （OS） were 70％/83％, the 2-year disease-specific survival rates （DSS） were 73％/92％, and the 2-year disease-free survival rates （DFS） were 68％/71％. In regard to the stage of hypopharyngeal cancer/laryngeal cancer 100％/100％ had stageⅢ, 75％/88％ had stageⅣA, and 0％/100％ had stageⅣB respectively. There was a significant difference in the statistical analysis between the 2-year DSSs with 62％ for the group receiving one course of chemotherapy during CCRT and with 90％ for another group receiving two or three courses. The 2-year laryngeal preservation rate （LPR） was 89％ in all cases and in regard to T-stage 100％ had T2, 91％ had T3, and 81％ had T4. As to severe long-term adverse events, there was only one case, who required insertion of a gastric tube for more than one year.
To conclude, our therapeutic approach of using CCRT for hypopharyngeal and laryngeal cancers showed successful improvements of the survival rates and the LPRs especially in patients with higher T-stages. Furthermore, the occurrence rates of severe long-term adverse events in our approach were smaller than those found in other reports.
